|  |  |  |
| --- | --- | --- |
| **Supplemental Table 1** Medication historya | | |
| Medication | N = 275 | |
| Baclofen |  |  |
| Used for spasticity, n (%) | 140 | (50.9) |
| Used, indication unknown, n (%) | 5 | (1.8) |
| Use not mentioned, n (%) | 130 | (47.3) |
| Benzodiazepines |  |  |
| Used for spasticity, n (%) | 24 | (8.7) |
| Used, indication unknown, n (%) | 14 | (5.1) |
| Use not mentioned, n (%) | 237 | (86.2) |
| Dantrolene |  |  |
| Used for spasticity, n (%) | 4 | (1.5) |
| Used, indication unknown, n (%) | 1 | (0.4) |
| Use not mentioned, n (%) | 270 | (98.2) |
| Gabapentin |  |  |
| Used for spasticity, n (%) | 27 | (9.8) |
| Used, indication unknown, n (%) | 20 | (7.3) |
| Use not mentioned, n (%) | 228 | (82.9) |
| Imidazolines |  |  |
| Used for spasticity, n (%) | 28 | (10.2) |
| Used, indication unknown, n (%) | 4 | (1.5) |
| Use not mentioned, n (%) | 243 | (88.4) |
| Pregabalin |  |  |
| Used for spasticity, n (%) | 7 | (2.5) |
| Used, indication unknown, n (%) | 9 | (3.3) |
| Use not mentioned, n (%) | 259 | (94.2) |
| Other oral medication |  |  |
| Used for spasticity, n (%) | 20 | (7.3) |
| Used, indication unknown, n (%) | 4 | (1.5) |
| Use not mentioned, n (%) | 251 | (91.3) |
| aMay have taken prior to study, at baseline of study, and/or concurrently during study | | |

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  |  |  |  | |  | |  | |  |  | |
| **Supplemental Table 2** Percentage of patients with clinical presentations treated at each session | | | | | | | | | | | | | | | | | |
| **Clinical** | | | | **Tx 1** | | **Tx 2** | | **Tx 3** | | | **Tx 4** | | **Tx 5** | **Tx 6** | **Tx 7** | **Tx 8** |
| **presentation, n (%)** | | | | **n = 275** | | **n = 243** | | **n = 213** | | | **n = 184** | | **n = 148** | **n = 109** | **n = 79** | **n = 27** |
| Adducted/internally rotated shoulder | | | | 69 (25.1) | | 75 (30.9) | | 62 (29.1) | | | 58 (31.5) | | 48 (32.4) | 40 (36.7) | 28 (35.4) | 12 (44.4) |
| Adducted thigh | | | | 26 (9.5) | | 23 (9.5) | | 22 (10.3) | | | 18 (9.8) | | 13 (8.8) | 11 (10.1) | 8 (10.1) | 0 (0.0) |
| Clenched fist | | | | 194 (70.5) | | 165 (67.9) | | 149 (70.0) | | | 135 (73.4) | | 106 (71.6) | 81 (74.3) | 57 (72.2) | 21 (77.8) |
| Equinovarus foot | | | | 184 (66.9) | | 167 (68.7) | | 146 (68.5) | | | 125 (67.9) | | 100 (67.6) | 77 (70.6) | 59 (74.7) | 22 (81.5) |
| Flexed elbow | | | | 185 (67.3) | | 155 (63.8) | | 132 (62.0) | | | 120 (65.2) | | 95 (64.2) | 66 (60.6) | 49 (62.0) | 17 (63.0) |
| Flexed hip | | | | 9 (3.3) | | 4 (1.6) | | 6 (2.8) | | | 6 (3.3) | | 6 (4.1) | 3 (2.8) | 2 (2.5) | 2 (7.4) |
| Flexed knee | | | | 42 (15.3) | | 37 (15.2) | | 26 (12.2) | | | 24 (13.0) | | 19 (12.8) | 14 (12.8) | 15 (19.0) | 3 (11.1) |
| Flexed toe | | | | 38 (13.8) | | 33 (13.6) | | 29 (13.6) | | | 28 (15.2) | | 22 (14.9) | 13 (11.9) | 6 (7.6) | 2 (7.4) |
| Flexed wrist | | | | 138 (50.2) | | 118 (48.6) | | 95 (44.6) | | | 83 (45.1) | | 72 (48.6) | 54 (49.5) | 33 (41.8) | 17 (63.0) |
| Intrinsic plus hand | | | | 35 (12.7) | | 34 (14.0) | | 32 (15.0) | | | 32 (17.4) | | 29 (19.6) | 17 (15.6) | 14 (17.7) | 6 (22.2) |
| Other lower limb | | | | 18 (6.5) | | 14 (5.8) | | 15 (7.0) | | | 11 (6.0) | | 9 (6.1) | 7 (6.4) | 4 (5.1) | 2 (7.4) |
| Other upper limb | | | | 36 (13.1) | | 35 (14.4) | | 37 (17.4) | | | 33 (17.9) | | 37 (25.0) | 29 (26.6) | 23 (29.1) | 7 (25.9) |
| Pronated forearm | | | | 73 (26.5) | | 70 (28.8) | | 57 (26.8) | | | 56 (30.4) | | 44 (29.7) | 33 (30.3) | 22 (27.8) | 6 (22.2) |
| Stiff extended knee | | | | 31 (11.3) | | 25 (10.3) | | 22 (10.3) | | | 21 (11.4) | | 16 (10.8) | 14 (12.8) | 8 (10.1) | 4 (14.8) |
| Striatal/hyperextended/hitchhiker toe | | | | 20 (7.3) | | 20 (8.2) | | 14 (6.6) | | | 13 (7.1) | | 11 (7.4) | 4 (3.7) | 6 (7.6) | 1 (3.7) |
| Thumb-in-palm | | | | 46 (16.7) | | 26 (10.7) | | 30 (14.1) | | | 33 (17.9) | | 29 (19.6) | 17 (15.6) | 9 (11.4) | 3 (11.1) |
| Tx, treatment. | | | |  | |  | |  | | |  | |  |  |  |  |

|  |  |  |
| --- | --- | --- |
| **Supplemental Table 3** All nonserious and serious adverse events,  MedDRA terms |  |  |
|  | **Patients (*N*=275)** | |
|  | **Patients, *n* (%)** | **Events, *n*** |
| **All non-serious AEsa** | **94 (34.2%)** | **293** |
| **Blood and lymphatic system disorders** | 2 (0.7%) | 2 |
| Anaemia | 1 (0.4%) | 1 |
| Leukocytosis | 1 (0.4%) | 1 |
| **Cardiac disorders** | 2 (0.7%) | 2 |
| Angina pectoris | 1 (0.4%) | 1 |
| Cardiac failure congestive | 1 (0.4%) | 1 |
| **Congenital, familial and genetic disorders** | 1 (0.4%) | 1 |
| Cerebral palsy | 1 (0.4%) | 1 |
| **Ear and labyrinth disorders** | 1 (0.4%) | 1 |
| Ear pain | 1 (0.4%) | 1 |
| **Endocrine disorders** | 2 (0.7%) | 2 |
| Hypogonadism | 1 (0.4%) | 1 |
| Hypothyroidism | 1 (0.4%) | 1 |
| **Eye disorders** | 1 (0.4%) | 1 |
| Diplopia | 1 (0.4%) | 1 |
| **Gastrointestinal disorders** | 14 (5.1%) | 20 |
| Abdominal distension | 1 (0.4%) | 1 |
| Constipation | 7 (2.5%) | 8 |
| Diarrhoea | 1 (0.4%) | 1 |
| Dry mouth | 1 (0.4%) | 1 |
| Dyspepsia | 1 (0.4%) | 1 |
| Dysphagia | 3 (1.1%) | 3 |
| Gastrooesophageal reflux disease | 2 (0.7%) | 2 |
| Irritable bowel syndrome | 1 (0.4%) | 1 |
| Nausea | 1 (0.4%) | 1 |
| Stomatitis | 1 (0.4%) | 1 |
| **General disorders and administration site conditions** | 12 (4.4%) | 13 |
| Asthenia | 2 (0.7%) | 2 |
| Drug tolerance | 1 (0.4%) | 1 |
| Injection site pain | 1 (0.4%) | 1 |
| Oedema peripheral | 5 (1.8%) | 5 |
| Pain | 2 (0.7%) | 3 |
| Peripheral swelling | 1 (0.4%) | 1 |
| **Immune system disorders** | 4 (1.5%) | 4 |
| Drug hypersensitivity | 1 (0.4%) | 1 |
| Hypersensitivity | 1 (0.4%) | 1 |
| Seasonal allergy | 2 (0.7%) | 2 |
| **Infections and infestations** | 33 (12.0%) | 60 |
| Acute sinusitis | 1 (0.4%) | 1 |
| Bronchitis | 6 (2.2%) | 7 |
| Cellulitis | 2 (0.7%) | 2 |
| Dermatophytosis of nail | 1 (0.4%) | 1 |
| Device related infection | 1 (0.4%) | 1 |
| Diverticulitis | 1 (0.4%) | 1 |
| Fungal infection | 1 (0.4%) | 1 |
| Fungal skin infection | 1 (0.4%) | 1 |
| Furuncle | 1 (0.4%) | 1 |
| Gastroenteritis viral | 2 (0.7%) | 2 |
| Gastrointestinal infection | 1 (0.4%) | 1 |
| Gastrointestinal viral infection | 1 (0.4%) | 1 |
| Helicobacter infection | 1 (0.4%) | 1 |
| Hepatitis B | 1 (0.4%) | 1 |
| Hordeolum | 1 (0.4%) | 1 |
| Localised infection | 1 (0.4%) | 1 |
| Nasopharyngitis | 1 (0.4%) | 1 |
| Onychomycosis | 1 (0.4%) | 1 |
| Otitis media | 2 (0.7%) | 2 |
| Paronychia | 1 (0.4%) | 1 |
| Periodontitis | 2 (0.7%) | 2 |
| Pharyngitis | 1 (0.4%) | 1 |
| Pneumonia | 1 (0.4%) | 1 |
| Sinusitis | 3 (1.1%) | 4 |
| Tooth infection | 1 (0.4%) | 1 |
| Upper respiratory tract infection | 7 (2.5%) | 8 |
| Urinary tract infection | 8 (2.9%) | 11 |
| Vaginitis *gardnerella* | 1 (0.4%) | 1 |
| Viral upper respiratory tract infection | 2 (0.7%) | 2 |
| **Injury, poisoning, and procedural complications** | 26 (9.5%) | 40 |
| Contusion | 2 (0.7%) | 2 |
| Face injury | 1 (0.4%) | 1 |
| Fall | 15 (5.5%) | 20 |
| Fibula fracture | 1 (0.4%) | 1 |
| Foot fracture | 1 (0.4%) | 1 |
| Hand fracture | 1 (0.4%) | 1 |
| Humerus fracture | 3 (1.1%) | 3 |
| Laceration | 2 (0.7%) | 2 |
| Ligament sprain | 1 (0.4%) | 1 |
| Limb injury | 1 (0.4%) | 1 |
| Lumbar vertebral fracture | 1 (0.4%) | 1 |
| Meniscus injury | 1 (0.4%) | 1 |
| Muscle strain | 1 (0.4%) | 1 |
| Post procedural complication | 1 (0.4%) | 1 |
| Road traffic accident | 1 (0.4%) | 1 |
| Soft tissue injury | 1 (0.4%) | 1 |
| Stoma complication | 1 (0.4%) | 1 |
| **Investigations** | 5 (1.8%) | 5 |
| Blood cholesterol increased | 1 (0.4%) | 1 |
| Blood pressure increased | 1 (0.4%) | 1 |
| Grip strength decreased | 2 (0.7%) | 2 |
| Hepatic enzyme increased | 1 (0.4%) | 1 |
| **Metabolism and nutrition disorders** | 9 (3.3%) | 11 |
| Dehydration | 3 (1.1%) | 3 |
| Diabetes mellitus | 1 (0.4%) | 1 |
| Gout | 2 (0.7%) | 2 |
| Hyperlipidaemia | 1 (0.4%) | 1 |
| Hypokalaemia | 1 (0.4%) | 1 |
| Hyponatraemia | 1 (0.4%) | 1 |
| Hypovitaminosis | 1 (0.4%) | 1 |
| Vitamin B12 deficiency | 1 (0.4%) | 1 |
| **Musculoskeletal and connective tissue disorders** | 27 (9.8%) | 40 |
| Arthralgia | 5 (1.8%) | 7 |
| Arthritis | 2 (0.7%) | 2 |
| Back pain | 5 (1.8%) | 5 |
| Joint swelling | 2 (0.7%) | 2 |
| Muscle spasms | 1 (0.4%) | 1 |
| Muscular weakness | 7 (2.5%) | 7 |
| Musculoskeletal pain | 6 (2.2%) | 6 |
| Musculoskeletal stiffness | 2 (0.7%) | 2 |
| Osteoarthritis | 1 (0.4%) | 1 |
| Pain in extremity | 7 (2.5%) | 7 |
| **Nervous system disorders** | 20 (7.3%) | 25 |
| Aphasia | 1 (0.4%) | 1 |
| Cerebrovascular accident | 1 (0.4%) | 1 |
| Dizziness | 5 (1.8%) | 5 |
| Dysarthria | 1 (0.4%) | 1 |
| Headache | 4 (1.5%) | 4 |
| Hypoaesthesia | 1 (0.4%) | 1 |
| Multiple sclerosis relapse | 1 (0.4%) | 1 |
| Muscle spasticity | 5 (1.8%) | 5 |
| Seizure | 4 (1.5%) | 4 |
| Speech disorder | 1 (0.4%) | 1 |
| Transient ischaemic attack | 1 (0.4%) | 1 |
| **Psychiatric disorders** | 14 (5.1%) | 19 |
| Anxiety | 2 (0.7%) | 2 |
| Attention deficit/hyperactivity disorder | 1 (0.4%) | 1 |
| Depression | 5 (1.8%) | 5 |
| Hypervigilance | 1 (0.4%) | 1 |
| Insomnia | 5 (1.8%) | 5 |
| Mood altered | 1 (0.4%) | 1 |
| Psychotic disorder due to a general medical condition | 1 (0.4%) | 1 |
| Stress | 1 (0.4%) | 1 |
| Withdrawal syndrome | 1 (0.4%) | 2 |
| **Renal and urinary disorders** | 3 (1.1%) | 4 |
| Nephrolithiasis | 1 (0.4%) | 1 |
| Pollakiuria | 1 (0.4%) | 1 |
| Urinary incontinence | 1 (0.4%) | 1 |
| Urinary retention | 1 (0.4%) | 1 |
| **Reproductive system and breast disorders** | 3 (1.1%) | 4 |
| Benign prostatic hyperplasia | 1 (0.4%) | 1 |
| Erectile dysfunction | 2 (0.7%) | 3 |
| **Respiratory, thoracic, and mediastinal disorders** | 11 (4.0%) | 15 |
| Cough | 2 (0.7%) | 2 |
| Dysphonia | 1 (0.4%) | 1 |
| Nasal septum deviation | 1 (0.4%) | 1 |
| Nasal turbinate hypertrophy | 1 (0.4%) | 1 |
| Oropharyngeal pain | 1 (0.4%) | 1 |
| Productive cough | 1 (0.4%) | 1 |
| Pulmonary congestion | 1 (0.4%) | 2 |
| Rhinitis allergic | 3 (1.1%) | 3 |
| Rhinitis hypertrophic | 1 (0.4%) | 1 |
| Rhinorrhoea | 1 (0.4%) | 1 |
| Sleep apnoea syndrome | 1 (0.4%) | 1 |
| **Skin and subcutaneous tissue disorders** | 11 (4.0%) | 14 |
| Acne | 1 (0.4%) | 1 |
| Actinic keratosis | 1 (0.4%) | 1 |
| Decubitus ulcer | 1 (0.4%) | 1 |
| Dermatitis contact | 1 (0.4%) | 1 |
| Drug eruption | 1 (0.4%) | 1 |
| Ecchymosis | 1 (0.4%) | 1 |
| Eczema | 2 (0.7%) | 2 |
| Hyperhidrosis | 1 (0.4%) | 1 |
| Rash | 1 (0.4%) | 1 |
| Rash macular | 1 (0.4%) | 1 |
| Rash papular | 1 (0.4%) | 1 |
| Seborrhoeic dermatitis | 1 (0.4%) | 1 |
| Skin ulcer | 1 (0.4%) | 1 |
| **Vascular disorders** | 6 (2.2%) | 9 |
| Haematoma | 3 (1.1%) | 3 |
| Hypertension | 4 (1.5%) | 5 |
| Orthostatic hypotension | 1 (0.4%) | 1 |
| **All Serious Adverse Events** | 42 (15.3%) | 80 |
| **Blood and lymphatic system disorders** | 1 (0.4%) | 1 |
| Anaemia | 1 (0.4%) | 1 |
| **Cardiac disorders** | 6 (2.2%) | 7 |
| Acute myocardial infarction | 1 (0.4%) | 1 |
| Angina pectoris | 1 (0.4%) | 1 |
| Atrial fibrillation | 1 (0.4%) | 1 |
| Cardiac failure congestive | 1 (0.4%) | 1 |
| Coronary artery disease | 1 (0.4%) | 1 |
| Myocardial infarction | 2 (0.7%) | 2 |
| **Gastrointestinal disorders** | 7 (2.5%) | 9 |
| Ascites | 1 (0.4%) | 2 |
| Dysphagia | 1 (0.4%) | 1 |
| Gastrointestinal haemorrhage | 1 (0.4%) | 1 |
| Ileus | 1 (0.4%) | 1 |
| Pancreatitis acute | 1 (0.4%) | 1 |
| Rectal haemorrhage | 1 (0.4%) | 1 |
| Rectal ulcer | 1 (0.4%) | 1 |
| Vomiting | 1 (0.4%) | 1 |
| **General disorders and administration site conditions** | 4 (1.5%) | 5 |
| Abasia | 1 (0.4%) | 1 |
| Asthenia | 3 (1.1%) | 3 |
| Multiple organ dysfunction syndrome | 1 (0.4%) | 1 |
| **Hepatobiliary disorders** | 2 (0.7%) | 2 |
| Cholecystitis acute | 1 (0.4%) | 1 |
| Chronic hepatic failure | 1 (0.4%) | 1 |
| **Infections and infestations** | 11 (4.0%) | 14 |
| Clostridium difficile colitis | 1 (0.4%) | 1 |
| Pneumonia | 5 (1.8%) | 5 |
| Post procedural infection | 1 (0.4%) | 1 |
| Pyelonephritis | 1 (0.4%) | 1 |
| Pyonephrosis | 1 (0.4%) | 1 |
| Septic shock | 1 (0.4%) | 1 |
| Urinary tract infection | 2 (0.7%) | 3 |
| Urinary tract infection enterococcal | 1 (0.4%) | 1 |
| **Injury, poisoning, and procedural complications** | 6 (2.2%) | 10 |
| Fall | 2 (0.7%) | 2 |
| Hand fracture | 1 (0.4%) | 1 |
| Hip fracture | 1 (0.4%) | 1 |
| Jaw fracture | 1 (0.4%) | 1 |
| Laceration | 1 (0.4%) | 1 |
| Lower limb fracture | 1 (0.4%) | 1 |
| Upper limb fracture | 1 (0.4%) | 1 |
| Urinary retention postoperative | 1 (0.4%) | 1 |
| Wrist fracture | 1 (0.4%) | 1 |
| **Metabolism and nutrition disorders** | 3 (1.1%) | 4 |
| Dehydration | 1 (0.4%) | 1 |
| Hypokalaemia | 1 (0.4%) | 1 |
| Hyponatraemia | 1 (0.4%) | 1 |
| Metabolic acidosis | 1 (0.4%) | 1 |
| **Musculoskeletal and connective tissue disorders** | 3 (1.1%) | 3 |
| Joint stiffness | 1 (0.4%) | 1 |
| Muscular weakness | 1 (0.4%) | 1 |
| Scoliosis | 1 (0.4%) | 1 |
| **Neoplasms benign, malignant, and unspecified (including cysts and polyps)** | 2 (0.7%) | 2 |
| Brain neoplasm | 1 (0.4%) | 1 |
| Non-Hodgkin’s lymphoma | 1 (0.4%) | 1 |
| **Nervous system disorders** | 11 (4.0%) | 11 |
| Cerebrovascular accident | 2 (0.7%) | 2 |
| Encephalopathy | 1 (0.4%) | 1 |
| Generalised tonic-clonic seizure | 1 (0.4%) | 1 |
| Haemorrhage intracranial | 1 (0.4%) | 1 |
| Headache | 1 (0.4%) | 1 |
| Multiple sclerosis | 1 (0.4%) | 1 |
| Multiple sclerosis relapse | 1 (0.4%) | 1 |
| Muscle spasticity | 1 (0.4%) | 1 |
| Seizure | 1 (0.4%) | 1 |
| Slow speech | 1 (0.4%) | 1 |
| **Psychiatric disorders** | 1 (0.4%) | 1 |
| Depression | 1 (0.4%) | 1 |
| **Renal and urinary disorders** | 4 (1.5%) | 5 |
| Acute kidney injury | 2 (0.7%) | 2 |
| End stage renal disease | 1 (0.4%) | 2 |
| Renal artery stenosis | 1 (0.4%) | 1 |
| **Respiratory, thoracic, and mediastinal disorders** | 3 (1.1%) | 4 |
| Dyspnoea | 2 (0.7%) | 3 |
| Respiratory failure | 1 (0.4%) | 1 |
| **Vascular disorders** | 1 (0.4%) | 2 |
| Arteriosclerosis | 1 (0.4%) | 1 |
| Hypotension | 1 (0.4%) | 1 |
| aOne patient has a record in the nonserious AE dataset; no further details were provided. | | |
| If a patient had the same event more than once, they are only counted once for the patient counts and percentages. | | |
| Total events include what may be multiple occurrences of the same event for a patient.  AE, adverse event; MedDRA, Medical Dictionary for Regulatory Activities Terminology. | | |